Editas Medicine Inc
$ 2.50
2.46%
12 Jun - close price
- Market Cap 383,655,000 USD
- Current Price $ 2.50
- High / Low $ 2.60 / 2.43
- Stock P/E N/A
- Book Value 0.04
- EPS -1.14
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -3.26 %
- 52 Week High 4.54
- 52 Week Low 1.66
About
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$5.78
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-09 | 2025-11-10 | 2025-08-12 | 2025-05-12 | 2025-03-05 | 2024-11-04 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-03 | 2023-08-02 |
| Reported EPS | -0.26 | -0.06 | -0.28 | -0.32 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.23 | -0.55 | -0.56 |
| Estimated EPS | -0.24 | -0.2302 | -0.38 | -0.38 | -0.59 | -0.3286 | -0.77 | -0.71 | -0.64 | -0.54 | -0.58 | -0.77 |
| Surprise | -0.02 | 0.1702 | 0.1 | 0.06 | -0.33 | -0.2214 | 0.02 | -0.11 | -0.12 | 0.31 | 0.03 | 0.21 |
| Surprise Percentage | -8.3333% | 73.9357% | 26.3158% | 15.7895% | -55.9322% | -67.3767% | 2.5974% | -15.493% | -18.75% | 57.4074% | 5.1724% | 27.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EDIT
2026-06-06 04:39:38
RA CAPITAL MANAGEMENT, L.P. has acquired 8,889,000 shares of Editas Medicine Inc for $3.57 per share, making it a new holding and a 5.80% position in the biotechnology firm's portfolio. This strategic investment, impacting the firm's portfolio by 0.34%, highlights a continued interest in genome editing technology despite Editas Medicine Inc's current overvaluation and financial challenges. Editas Medicine Inc, a USA-based company specializing in CRISPR technology, faces volatility with its stock price at $2.71, yet shows revenue and EBITDA growth.
2026-06-06 04:39:38
COMMODORE CAPITAL LP has acquired a significant 9.90% stake in Editas Medicine Inc, purchasing 16,045,802 shares at $3.08 each. This strategic investment, valued at $1.73 billion, integrates Editas Medicine, a clinical-stage biotechnology company focused on CRISPR technology, into COMMODORE CAPITAL LP's portfolio, enhancing its presence in the healthcare sector. Despite Editas Medicine Inc's current financial challenges, including an "overvalued" stock rating and low GF-Score, the acquisition underscores COMMODORE CAPITAL LP's commitment to genomic medicine and could provide crucial support for Editas's advancement in gene editing.
2026-06-05 20:38:56
Linda Burkly, EVP, Chief Scientific Officer of Editas Medicine (EDIT), sold 731 shares worth $1,975 on June 3, 2026, at a weighted average price of $2.7011 per share. This sale was a non-discretionary transaction executed under an automatic sales instruction plan adopted on July 3, 2023, to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. Following the transaction, Burkly directly holds 67,297 shares of Editas Medicine common stock.
2026-06-05 20:38:56
Editas Medicine's CFO, Amy Parison, sold 464 shares of common stock at a weighted average price of $2.7010 per share on June 3, 2026. This sale was conducted under a pre-established automatic plan to cover tax withholding obligations from vested restricted stock units and was not a discretionary trade. Following the transaction, she directly holds 14,970 shares of Editas Medicine common stock.
2026-06-05 20:38:56
Editas Medicine CEO Gilmore O’Neill sold 15,380 shares of common stock for $41,542 on June 3, 2026. This sale was not a discretionary trade but rather to cover tax withholding obligations from vested restricted stock units. Despite a recent 14% stock decline, shares are up 66% over the last year, and the stock is considered undervalued by InvestingPro analysis.
2026-06-05 20:38:56
Editas Medicine CFO Amy Parison sold 464 shares of company common stock worth $1,253 on June 3, 2026. This transaction was executed to cover tax withholding obligations associated with restricted stock unit vesting and was part of a pre-established automatic sales plan. Following the sale, Ms. Parison directly holds 14,970 shares, while the company's stock has seen a recent decline but remains up year-to-date.
